1978-59-2

Basic information

• Product Name: 4-(4-Halophenyl)-1,2,3,6-terahydropyridinehydrochloride
• Synonyms: 4-(4-Halophenyl)-1,2,3,6-terahydropyridinehydrochloride;4-FLUOROPHENYL-1,2,3,6-TETRAHYDROPYRIDINE;Pyridine, 4-(4-fluorophenyl)-1,2,3,6-tetrahydro-
• CAS NO: 1978-59-2
• Molecular Formula: C₁₁H₁₂FN
• Molecular Weight: 177.22
• Mol File: 1978-59-2.mol

Chemical Properties

• Boiling Point: 264°Cat760mmHg
• Flash Point: 113.4°C
• Appearance: /
• Density: 1.092g/cm³
• Vapor Pressure: 0.00997mmHg at 25°C
• Refractive Index: 1.534
• PKA: 9.34±0.10(Predicted)
• CAS DataBase Reference: 4-(4-Halophenyl)-1,2,3,6-terahydropyridinehydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Halophenyl)-1,2,3,6-terahydropyridinehydrochloride(1978-59-2)
• EPA Substance Registry System: 4-(4-Halophenyl)-1,2,3,6-terahydropyridinehydrochloride(1978-59-2)

Safety Data

• Hazardous Substances Data: 1978-59-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-Halophenyl)-1,2,3,6-tetrahydropyridine hydrochloride is used as a pharmaceutical intermediate for the development of new drugs. Its unique structure and potential biological activity make it a promising candidate for the treatment of various medical conditions.
Used in Medicinal Research:
In the field of medicinal research, 4-(4-Halophenyl)-1,2,3,6-tetrahydropyridine hydrochloride serves as a valuable compound for studying its potential therapeutic effects. Further research and development of this chemical could lead to the discovery of new drugs with novel mechanisms of action and improved efficacy.
Used in Drug Formulation:
The hydrochloride salt form of 4-(4-Halophenyl)-1,2,3,6-tetrahydropyridine makes it suitable for use in pharmaceutical formulations, allowing for the development of drugs with improved solubility and bioavailability. This enhances the compound's potential for therapeutic applications in various medical conditions.

InChI:InChI=1/C11H12FN/c12-11-3-1-9(2-4-11)10-5-7-13-8-6-10/h1-5,13H,6-8H2

Upstream product

• 1978-61-6 4-(4-fluorophenyl)-1,2,3,6-tetrahydropyridine hydrochloride 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 163630-89-5 4-(4-fluorophenyl)-1,2,3,6-tetrahydro-1-(phenylmethyl)pyridine 
• 163631-02-5 1-benzyl-4-(4-fluorophenyl)-4-hydroxypiperidine 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 352-13-6 4-flourophenylmagnesium bromide 
• 553631-05-3 tert-butyl 4-hydroxy-4-(4-fluorophenyl)-1-piperidinecarboxylate 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 138647-52-6 4-(4-fluorophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 1765-93-1 4-fluoroboronic acid 
• 163630-90-8 4-(4-Fluoro-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid 2,2,2-trichloro-ethyl ester 
• 350-40-3 2-(4-fluorophenyl)-1-propene 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 

Downstream Products

• 508239-22-3 8-[4-(4-Fluorophenyl)-1,2,3,6-tetrahydropyridin-1-ylmethyl]-2-(2-furyl)-5-[2-(1-pyrrolidinyl)ethylamino][1,2,4]triazolo[1,5-c]pyrimidine 
• 508239-54-1 8-[4-(4-Fluorophenyl)-1,2,3,6-tetrahydropyridin-1-ylmethyl]-2-(2-furyl)-5-(2-morpholinoethylamino)[1,2,4]triazolo[1,5-c]pyrimidine 
• 775-58-6 4-bromo-4-(4-fluoro-phenyl)-piperidine; hydrobromide 
• 39795-58-9 4-(4-fluorophenyl)pyridine 
• 152565-98-5 C₂₀H₂₀FNO 

Relevant articles and documents

FLUORINE-CONTAINING COMPOUND AND ANTI-CANCER MEDICAL USE THEREOF

The present invention provides a fluorine-containing compound shown in Formula II/III and its anti-cancer medical use.

Monoamine Oxidase (MAO-N) Whole Cell Biocatalyzed Aromatization of 1,2,5,6-Tetrahydropyridines into Pyridines

A sustainable MAO-N biocatalyzed process for the synthesis of pyridines from aliphatic tetrahydropyridines (THP) has been developed. Pyridine compounds were synthesized under mild reaction conditions and with high conversion, exploiting MAO-N whole cells as aromatizing biocatalysts. The kinetic profile of the whole cell biocatalytic transformation was finally investigated via in situ 19F NMR.

VMAT INHIBITORY COMPOUNDS

Disclosed herein are compounds that bind to the vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions comprising those compounds, and methods of treatment using said compounds and pharmaceutical compositions.

Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARα/γ dual agonists

Aryl-tetrahydropyridine derivatives were prepared and their PPARα/γ dual agonistic activities were evaluated. Among them, compound (S)-5b was identified as a potent PPARα/γ dual agonist with an EC50 of 1.73 and 0.64 μM in hPPARα and γ, respectively. In diabetic (db/db) mice, compound (S)-5b showed good glucose lowering efficacy and favorable pharmacokinetic properties.

METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Design and synthesis of orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugs

A novel series of TNF inhibitors was identified based on the screening of existing MMP inhibitor libraries. Further SAR optimization led to the discovery of a novel lead compound. Its synthesis, efficacy in experimental animal models, and pharmacokinetic

N-sulfonylurea apoptosis promoters

Compounds having the formula are apoptosis promoters. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

The N-(2-acetoxyethyl) group as a new photolabile protecting group

The N-(2-acetoxyethyl) group can be cleaved by a photoinduced single electron transfer to 4,4'-dimethoxybenzophenone. (C) 2000 Published by Elsevier Science Ltd.

σ Ligands with subnanomolar affinity and preference for the σ2 binding site. 1. 3-(ω-Aminoalkyl)-1H-indoles

A series of 4-(1H-indol-3-yl)-1-butyl-substituted 4-phenylpiperidines, 4- phenyl-1,2,3,6-terrahydropyridines, and 4-phenylpiperazines was synthesized. The phenyl group was optionally substituted with 4-fluoro or 2-methoxy substituents. High affinity for both σ1 and σ1 binding sites was achieved with these compounds. Additionally, these compounds had relatively high affinity for serotonin 5-HT(1A) and 5-HT(2A), dopamine D2, and adrenergic α1 receptors. Introduction of a 4-fluorophenyl substituent at the indole nitrogen atom rendered very selective σ2 ligands with subnanomolar affinity for the σ2 binding site. The prototype of such a compound was 1-(4- fluorophenyl)-3-[4-[4-(4-fluorophenyl)-1-piperidinyl]-1-butyl]-1H-indole, 11a (code no. Lu 29-253). This compound had the following binding affinities: IC50 (σ1) = 16 nM, IC50 (σ2) = 0.27 riM, IC50 (5-HT(1A)) = 22 000 nM, IC50 (5-HT(2A)) = 270 nM, IC50 (D2) = 4200 nM, IC50 (α1) = 220nM. Spiro-joining of the phenyl and the piperidine rings into a spiro[isobenzofuran-1(3H),4'-piperidinel ring system resulted in even more selective compounds. Variations of the 1-substituent at the indole and of the chain length of the alkylene spacer group were studied. The optimal compound was the spiro analogue of compound 11a. This compound is 1'-14-[1(4- fluorophenyl)-1H-indol-3-yl]-1-butyl]spiro[isobenzofuran-1(3H),4'- piperidine], 14f (code no. Lu 28-179), with the binding affinities: IC50 (σ1) = 17 nM, IC50 (σ2) = 0.12 nM, IC50 (5-HT(1A)) = 21 000 nM, IC50 (5-HT(2A)) = 2000 nM, IC50 (D2) = 800 nM, IC50 (α1) = 330 nM. However, the most selective σ2 versus σ1 ligand was the tropane derivative 1-(4-fluorophenyl)-3-[4-[3-(4-fluorophenyl)-8- azabicyclo[3.2.1]oct-2-en-8-yl]-1-butyl]-1H-indole, 15a. This compound had the following binding affinities: IC50 (σ1) = 1200 nM, IC50 (σ2) = 2.5 nM. Potent anxiolytic activity in the black/white box exploration test in rats was found with the two most prominent σ2 ligands Lu 29-253 and Lu 28- 179. Good penetration into the CNS was documented both after subcutaneous and peroral administration of Lu 28-179 by ex vivo binding studies. Long duration of action was demonstrated both in ex vivo binding (T(1/2) ~ 20 h) and in the black/white box exploration test.